Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of BMS-986466 + adagrasib ± cetuximab in KRAS G12C-mutant advanced solid tumors
2023-505070-15-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of BMS-986466 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic adenocarcinoma (PDAC) and 1 more (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of dose-limiting toxicities and safety events and Overall response rate by BICR. Started Jan 2024; status: completed.
02
Drugs
BMS-986466
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)biliary cancer
Beyond the preview
Go deeper on 2023-505070-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505070-15-00.